Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Tagworks Pharmaceuticals BV
Kelonia Therapeutics, Inc.
Celtic Biotech Ltd
Baylor College of Medicine
Astellas Pharma Inc
Singlomics (Beijing DanXu) Biopharmaceuticals Co., Ltd.
Boehringer Ingelheim
Astellas Pharma Inc
Janssen Research & Development, LLC
AbbVie
Montefiore Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Iambic Therapeutics, Inc
Amgen
TOLREMO therapeutics AG
FBD Biologics Limited
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Johnson & Johnson Enterprise Innovation Inc.
Zymeworks BC Inc.
Kexing Biopharm Co., Ltd.
National Institutes of Health Clinical Center (CC)
Calibr, a division of Scripps Research
Revolution Medicines, Inc.
Bristol-Myers Squibb
Conjupro Biotherapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Epsilogen Ltd
Coherus Oncology, Inc.
GlaxoSmithKline
Conjupro Biotherapeutics, Inc.
Medical College of Wisconsin
DeuterOncology
Alterome Therapeutics, Inc.
First Hospital of China Medical University
Biocon Limited
National Institutes of Health Clinical Center (CC)
Pfizer
Boehringer Ingelheim
Amgen
Pheon Therapeutics
University of California, San Francisco
Inmune Bio, Inc.
Vividion Therapeutics, Inc.
Hoffmann-La Roche
Pfizer